Luminex CEO Patrick Balthrop this week provided an update on the Austin, Texas-based company's molecular diagnostics portfolio, characterizing Luminex's infectious disease tests as experiencing "continued momentum" in the marketplace and describing talks with the US Food and Drug Administration regarding the company's Neoplex newborn screening assay as "ongoing."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.